Related Experiment Videos
IIb's are not IIb's
D J Kereiakes1, J P Runyon, T M Broderick
1The Carl and Edyth Lindner Center for Research and Education, Cincinnati, Ohio, USA.
Insights
Platelet glycoprotein IIb/IIIa inhibitors improve outcomes in cardiovascular procedures. However, agents like abciximab show distinct receptor binding and survival benefits compared to others, suggesting unique mechanisms beyond simple receptor blockade.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Biochemistry
Background:
- Platelet glycoprotein (GP) IIb/IIIa receptor blockade is crucial for improving outcomes in percutaneous coronary intervention (PCI) and acute coronary syndromes.
- Current GP IIb/IIIa inhibitors exhibit significant differences in pharmacodynamics, pharmacokinetics, and receptor affinity.
Purpose of the Study:
- To compare the distinct binding characteristics and clinical outcomes associated with different GP IIb/IIIa receptor antagonists.
- To investigate the mechanisms underlying observed survival advantages with specific agents.
Main Methods:
- Analysis of pharmacodynamic and pharmacokinetic profiles of abciximab, eptifibatide, and tirofiban.
- Examination of differential binding sites on the GP IIb/IIIa receptor.
- Review of clinical trial data and practice outcomes comparing these agents post-PCI.
Main Results:
- Abciximab exhibits high affinity and prolonged receptor action, unlike eptifibatide and tirofiban which have lower affinity and shorter durations.
- Abciximab binds to additional receptors (CD11b/18 and αvβ3), potentially contributing to its observed survival advantage post-PCI.
- No survival benefit has been consistently observed with eptifibatide or tirofiban therapy for PCI.
Conclusions:
- The common affinity for the GP IIb/IIIa receptor does not fully explain agent-specific benefits.
- Abciximab's unique binding properties and additional receptor interactions may underlie its superior survival outcomes in PCI.
- Further research is needed to elucidate the precise mechanisms driving differential clinical benefits among GP IIb/IIIa inhibitors.
Abstract:
Platelet glycoprotein (GP) IIb/IIIa receptor blockade improves clinical outcomes after percutaneous coronary intervention (PCI) and for patients who present with non-ST-segment elevation acute coronary syndromes. Although this class of therapeutic agents has been defined by a common affinity for the platelet GP IIb/IIIa receptor, the 3 currently available agents differ markedly in pharmacodynamic and pharmacokinetic profile as well as receptor affinity. Differential (separate) binding sites on the GP IIb/IIIa receptor explain the observation that abciximab binding to platelets is not influenced by either tirofiban or eptifibatide. Abciximab (ReoPro, chimeric 7E3 Fab) is a low K(d) (high affinity) agent with a very short plasma t(1/2) and a prolonged duration of action at the platelet target receptor. Eptifibatide and tirofiban are high K(d) (low affinity) agents with a relatively long plasma t(1/2) and short duration of action at the platelet target receptor. These pharmacodynamic differences underlie the phenomena of gradual redistribution in abciximab binding and smooth tapering of abciximab antiplatelet effect after discontinuation of therapy. Furthermore, abciximab demonstrates affinity for both the CD11b/18 (alpha(m)beta(2) or MAC 1) and alpha(V)beta(3) (vitronectin) receptors. Although a survival advantage in favor of abciximab has been observed after PCI in both randomized controlled trials and high-volume clinical practice, no survival benefit has been observed to date after eptifibatide or tirofiban therapy for PCI. The mechanism of survival advantage after abciximab therapy has not been defined but may be distinct from the degree of platelet GP IIb/IIIa receptor inhibition during the duration of intravenous treatment. Although this important new "class" of therapeutic agent was simplistically defined by a common affinity for the GP IIb/IIIa receptor, this solitary unifying attribute may not define agent-specific benefit.